Generate Biomedicines disclosed positive Phase 1 clinical trial data for its drug candidate, GB-0895, after posters for the European Respiratory Society Congress 2026 were inadvertently released early. The data shows a single dose of GB-0895 provides durable anti-inflammatory activity for at least six months in patients with asthma and Chronic Obstructive Pulmonary Disease (COPD).
Key Details
- Phase 1 Results: A single 300 mg subcutaneous injection of GB-0895 achieved maximal suppression of key inflammatory biomarkers (BEC, FeNO, IL-5, IL-13) for at least 6 months in both asthma and COPD cohorts.
- Dosing Potential: The drug was well-tolerated and demonstrated a half-life of approximately 98 days, supporting the potential for a single injection, every-6-month treatment regimen.
- Clinical Advancement: GB-0895 is being advanced in two ongoing global Phase 3 studies (SOLAIRIA-1 & SOLAIRIA-2) for patients with severe uncontrolled asthma.